Fact CheckerSign in

NCT07911683Not yet recruitingPhase 2

Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma

A Phase 2 Global, Single-Arm Study of BGB-B2033 Monotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Anti-PD-1/PD-L1 Therapies

Source: ClinicalTrials.gov · Last updated 3 Nov 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapies.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
100 (estimated)
First submitted
27 Oct 2026
Start date
30 Nov 2026
Primary completion date
31 Mar 2028
Lead sponsor
BeOne Medicines
NCT number
NCT07911683
EU CT number
2026-528408-32-00

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 100
  • From 30 Nov 2026 to the primary completion date, 31 Mar 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous treatment targeting glypican-3 (GPC3) or 4-1BB.
  • A history of previous or current encephalopathy, a condition that affects brain function.

Other illness

  • Active leptomeningeal disease or uncontrolled and untreated brain metastases.
  • Radiographic evidence of tumor thrombosis involving the inferior vena cava or right atrium of the heart.
  • A history of liver transplantation.
  • Untreated chronic hepatitis B or chronic HVB carries with HVB DNA \> 2000 IU/mL at screening
    • Note: Other eligibility criteria may apply.

Other

  • Presence of clinically significant ascites (≥ Grade 2)

Who the study is looking for

  • Participants must have histologically confirmed hepatocellular carcinoma (HCC) that cannot be treated with curative surgery or locoregional therapy (LRT), or have disease that has progressed after surgery and/or locoregional therapy.
  • Participants must have documented disease progression or intolerance after at least one prior line of systemic therapy containing an anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) therapy.
  • Participants must have at least one measurable tumor lesion, as assessed according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1).
  • Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Participants must have adequate organ function, as determined by laboratory tests performed during screening.
  • Participants must be willing to use effective birth control during the study, as required by the study protocol.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.